Friday, 20 Apr 2018

You are here

Good News from ACR17 - Gout

The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content - http://acr17.rheumnow.com/category/gout-crystal/

Specific items:

  • Treatment of hyperuricemia to prevent incident dementia? Some data suggests this. Abstract #2076
  • PossibleGout and OA connection? Human cartilage increases amount and size of MSU crystals. Abstract #2896 http://ow.ly/ABLg30fM2gw
  • Low Uric acid may raise the risk of dementia. Abstract #2080
  • Lower coffee consumption is associated with gout!  Abstract #2066
  • Allopurinol and Febuxostat in lowes the risk of Dementia. Yes you read that right! Jas Singh et al. Abstract #2076
  • Both generic and environmental factors influence the fractional excretion of uric acid Abstract #2061
  • Hyperuricemia is associated with more rapid knee osteoarthritis progression. A&R 2017
  • Tollerizing pegloticase regimen decreases infusion reactions in the TRIPLE study Abstract #1141
  • Gout is under treated people… need to get better  Abstract #1121
  • If you have gout and type II diabetes you have worse gout. More tophi and erosions. Abstract #1118
  • Uncontrolled gout is associated with more heart failure so treat gout effectively. Abstract #1119
  • Risk for CV events lower with the new start probenecid (rather than allopurinol) for older >65 yo patients Abstract #159
  • Dr. Daniel Solomon YR in Review – the DASH diet decrease gout risk https://doi.org/10.1136/bmj.j1794 
  • Diuretics don’t seem to impact hugely on gout treatment objectives in this study Abstract #1129
  • Patients aren’t getting to urate target in gout when treated with allopurinol. Are we using enough? Abstract #166
  • Do we need to change the label ‘gout’ ?!?!? Has negative stereotypes  Abstract #1107
  • Patients with gout have their XOI stopped when they present with AKI. Evidence free zone and makes gout Rx harder. Abstract #1116
  • Gout patients more likely to achieve sUA goal< 6 mg/dL if managed by a rheumatologist. Go team Rheum! Abstract #166
  • Pre-Rx with methylprednisolone superior to HC as prophylaxis for pegloticase w/ greater drug survival  Abstract #213 https://buff.ly/2hKNl3y
  • Double contour sign - earliest sign of uric acid deposition obs in asymptomatic gout pts. Abstract #250 http://ow.ly/YZtb30fDVzZ
  • US of MTP1, distal patellar/triceps tendons, talar + femoral cartilage for MSU in possible gout Abstract #249
  • FORTUNE1: stepwise  Uloric dose comparable to colchicine+Uloric in flare prevention during introductory Rx 
  • Cankinumab reduces CV events, decreases risk of gout & malignancy. Higher infection risk  #YearInReview
  • “Gout patients can have septic arthritis and sickle cell pts can also have gout. Keep this in mind during your nex sickle cell crisis differential diagnoses.”  – J Cush, MD (Rheumatology Roundup). 

Gout Videos

Dr. Jack Cush: When Asymptomatic Hyperuricemia Should Be Treated 

 

Dr. Arthur Kavanaugh: Gout, OA Posters

 

Dr. Ken Saag: Update on Gout Therapy

 

Dr. Janet Pope: Gout Gamechangers 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Unmet Needs in Calcium Pyrophosphate Deposition Disease

Abhishek et al have written on the results of an international survey of crystal arthritis experts and identified the unmet needs  regarding calcium pyrophosphate crystal deposition (CPPD) - research, classification, diagnosis and management.

CPPD is a highly prevalent condition with a range of manifestations that may lead to pain, synovitis and joint damage, especially in the elderly.

FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk

Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes. 

In the study, 9795 adults (age 50–75 years) with type 2 diabetes were randomized to receive fenofibrate 200 mg per day or placebo and followed for up to 5 years.

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

The author and experts interviewed believe that the pipeline of new drugs for gout will fuel the future of evidence-based care and more informed lifestyle instruction.

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat. (Citation source bit.ly/2HtUEaz)